Quick summary: The imminent United Kingdom arrival of the weight loss drug Wegovy in a daily tablet format could significantly expand therapeutic access for the estimated 2.5 million people currently managing obesity through self injection. Clinical trial data indicates that the oral semaglutide option yields an average 14% reduction in body weight by mimicking satiety hormones, offering an appealing and stable storage alternative for roughly a third of clinically eligible adults who previously avoided treatment due to needle anxiety. These pharmaceutical developments carry massive weight for public policy and healthcare practice, providing a highly scalable intervention to lower the structural health burdens of cardiovascular disease and type 2 diabetes while fundamentally transforming long term population well being.
Weight loss jabs have taken the UK by storm as the country looks to tackle its £100bn-a-year obesity crisis, with an estimated 2.5 million people currently taking them. Now, a new development could see that number skyrocket: the arrival of Wegovy in tablet form.
Already approved and prescribed in the US since the start of the year, UK patients could see the pill become available in the coming months, pending anticipated regulatory decisions.
Jason Murphy, Head of Pharmacy and weight loss expert at Chemist4U, explains how the medication works, who will be eligible, and what patients can expect.
How they work
“Weight loss pills have the same active ingredient, semaglutide, as the weight loss injection Wegovy, and work in exactly the same way. This means they mimic the naturally occurring GLP-1 hormone, ensuring you feel fuller faster and have fewer cravings and a reduced urge to snack.”
How to take them
Wegovy tablets are a once-daily pill taken first thing in the morning on an empty stomach with no more than 120ml of plain water. To aid absorption, they should be taken at least 30 minutes before eating, drinking, or taking other medications.
Who is eligible
Since Wegovy tablets are not yet available in the UK, exact eligibility criteria remain unconfirmed. Murphy says they will likely mirror the injection’s requirements. Patients will probably need a BMI over 30, or a BMI over 27 alongside a weight-related condition such as Type 2 Diabetes. The tablets would not be suitable for those allergic to semaglutide, with a family history of thyroid cancer, or with certain pancreas or gallbladder issues, nor for those who are pregnant, planning to become pregnant, or breastfeeding.
“Individuals are encouraged to share their full medical history before starting treatment and to discuss any concerns with their prescriber to ensure the most suitable care.”
Side effects
“Similar to weight loss injections, Wegovy tablets may cause some side effects, but not everybody will get them. They are more common when you first start treatment, and you may experience nausea, diarrhoea, constipation, and other stomach problems.”
One distinction: “With the tablet, you will not experience localised side effects such as injection-site bruising that can occur with injections.”
Effectiveness
Clinical trials showed average weight loss of around 14% over 64 weeks at the 25 mg dose, compared with around 21% over 72 weeks for the 7.2 mg Wegovy injection. Murphy notes that individual results will vary.
Key differences from the injection
“For many, the convenience of a once-daily tablet will be far more appealing than weight loss injections. Our research shows that almost a third of adults in the UK who are clinically eligible for weight loss treatments were not pursuing them because treatment required self-injection.”
While the injection can be taken with or without food, the tablet requires an empty stomach, which may take some planning around morning routines. On the other hand, unlike injections, tablets require no refrigeration, offering greater flexibility, particularly when travelling. Since both forms share the same active ingredient, patients can also switch between the two without interrupting their treatment progress.
Experts note that the tablet format could broaden access through private providers or future NHS pathways, supporting efforts to reduce associated health burdens such as Type 2 Diabetes and Cardiovascular Disease. As with injections, the tablets are most effective when combined with diet and exercise.